Tumor idiotype antigen (Id)

Tumor idiotype antigen refers to the unique set of antigenic determinants, known as idiotopes, located within the variable regions of the immunoglobulin (Ig) or T-cell receptor (TCR) expressed by a malignant clone of B or T cells (NCI Dictionary of Cancer Terms, 2024). In B-cell malignancies such as follicular lymphoma, each tumor cell expresses a surface immunoglobulin with a unique amino acid sequence derived from the specific V(D)J recombination of the progenitor cell, making it a truly tumor-specific antigen that is absent on normal B cells (Levy et al., Blood, 2012). This high degree of specificity allows the idiotype to serve as a target for personalized active immunotherapy, most notably idiotype vaccines. These vaccines are typically produced by isolating the patient's specific idiotype protein, conjugating it to a carrier protein like Keyhole Limpet Hemocyanin (KLH), and administering it with an adjuvant to stimulate the patient's immune system to recognize and destroy the malignant clone (Schuster et al., Journal of Clinical Oncology, 2011). While early-phase trials demonstrated the ability of these vaccines to induce robust immune responses and extend remission, large-scale clinical development has been challenged by the logistical difficulties of custom manufacturing and inconsistent results in late-stage trials regarding overall survival benefits (Ai et al., Journal of Hematology & Oncology, 2015).

Other names

B-cell idiotypeImmunoglobulin idiotypeClonal idiotypeTumor-specific idiotypeT-cell receptor idiotype

Induction of a patient-specific active immune response, involving both humoral (anti-idiotype antibodies) and cellular (cytotoxic T-lymphocytes) components, directed against the unique variable regions of the monoclonal immunoglobulin or T-cell receptor expressed by malignant cells (Schuster et al., Journal of Clinical Oncology, 2011; Ai et al., Journal of Hematology & Oncology, 2015).